Overview

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.
Phase:
Phase 2
Details
Lead Sponsor:
MEI Pharma, Inc.
Collaborator:
Kyowa Kirin
Treatments:
Rituximab
Venetoclax